Efficient bioactive oligonucleotide‐protein conjugation for cell‐targeted cancer therapy

This work was supported byPlan Estatal de I+D+I 2013–201, Institto de Salud Carlos III and MINECO (co‐funding from FEDER) CTQ2017‐84415‐R, CTQ2014‐52588‐R, CP15/00167 and BIO2016‐76063, AGAUR (2017SGR865, 2017SGR114 and 017SGR229), MaratoTV3 (416/C/2013), andCIBER‐BBN Nanomets nd Nanoprother Intramural Projects. We used the CIBER‐BBN Nanotoxicology Platform and protein production and DLS have been partially performed by ICTS ”NANBIOSIS”, more specifically by the Protein Production Platform of CIBER‐BBN/IBB (http://www.nanbiosis.es/unit/u1‐protein‐production‐platform‐ppp/) and the Biomaterial Processing and Nanostructuring Unit (http://www.nanbiosis.es/portfolio/u6‐biomaterial‐processing‐and‐nanostructuring‐unit). M.V.C. and U.U. are supported by Miguel Servet contract from ISCIII and by PERIS program from the health department of la Generalitat de Catalunya, respectively. A.V. received an ICREA ACADEMIA Award. Authors thank the “Servei d’ Analisis Quimica” of the Universitat Autonoma de Barcelona and the “Serveis Cientifico‐Tecnics” of the Universitat de Barcelona for their help in the analysis of the mass spectra. Nanoparticle in‐silico representation modified from (34). Reprinted by permission of John Wiley & Sons, Inc.